| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w28355 |
| 来源ID | Working Paper 28355 |
| Private and Social Returns to R&D: Drug Development and Demographics | |
| Efraim Benmelech; Janice C. Eberly; Joshua L. Krieger; Dimitris Papanikolaou | |
| 发表日期 | 2021-01-18 |
| 出版年 | 2021 |
| 语种 | 英语 |
| 摘要 | Investment in intangible capital—in particular, research and development—increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer products such as pharmaceutical drugs with limited spillovers to productivity. We document that a significant share of R&D spending in the U.S. is done by pharmaceutical firms and is geared to developing drugs for the older patients. Increased life expectancy and quality of life among the elderly increases welfare but may not be reflected in estimates of total factor productivity. |
| 主题 | Health, Education, and Welfare ; Health ; Industrial Organization ; Industry Studies ; Development and Growth ; Innovation and R& ; D ; Growth and Productivity |
| URL | https://www.nber.org/papers/w28355 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/586026 |
| 推荐引用方式 GB/T 7714 | Efraim Benmelech,Janice C. Eberly,Joshua L. Krieger,et al. Private and Social Returns to R&D: Drug Development and Demographics. 2021. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w28355.pdf（213KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
